This comprehensive review emphasizes that a significant proportion of cancer cases are preventable through lifestyle modifications. The authors estimate that approximately 30–35% of cancer-related deaths are linked to dietary factors, 25–30% to tobacco use, 15–20% to infections, and the remainder to other factors such as physical inactivity, environmental pollutants, and
In her 1993 New York Times Magazine article, “Free Radicals: The Price We Pay For Breathing,” Natalie Angier delves into the paradox of oxygen metabolism: while essential for life, it inevitably leads to the production of free radicals—highly reactive molecules with unpaired electrons. These free radicals can damage cellular components
This 2017 review by Atilla Engin provides a comprehensive overview of the definitions and global prevalence of obesity and metabolic syndrome. Obesity is characterized by excessive fat accumulation that presents a risk to health, commonly assessed using body mass index (BMI). However, BMI does not account for fat distribution or
This 2009 systematic review and meta-analysis by Guh et al. evaluated the incidence of co-morbidities associated with overweight and obesity. The study analyzed 89 prospective cohort studies to estimate the relative risks (RRs) of various diseases in overweight and obese individuals compared to those with normal weight. Overweight (BMI 25–29.9
This 2017 review by Mattson, Longo, and Harvie, published in Ageing Research Reviews, examines the effects of intermittent fasting (IF) on health and disease processes in both animal models and humans. The authors discuss various IF regimens, including alternate-day fasting, the 5:2 diet, and time-restricted feeding, highlighting their potential benefits
This randomized controlled trial evaluated the effects of intravenous administration of growth hormone-releasing hormone (GHRH1-29NH2) and growth hormone-releasing peptide-2 (GHRP-2), individually and combined, on growth hormone (GH) secretion in healthy adult males. GHRP-2 alone significantly increased GH secretion (AUC: 6205.1 ± 3216.9 mU/l·min) compared to GHRH alone (AUC: 2061.2 ±
This clinical trial investigated the effects of synthetic growth hormone-releasing factors (GRF1-44, GRF1-40, and GRF1-29) on growth hormone (GH) secretion in healthy adult males. The study demonstrated that all three GRF analogs significantly increased GH secretion, with GRF1-44 producing the most substantial response. The findings suggest that synthetic GRFs can
This randomized controlled trial investigated the effects of continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 (GHRH1-29-NH2) in children with growth hormone deficiency (GHD). The treatment successfully restored physiological growth hormone (GH) secretion patterns, leading to increased insulin-like growth factor 1 (IGF-1) levels and improved growth velocity. These results suggest that GHRH1-29-NH2
This clinical trial investigated the effects of human calcitonin on growth hormone (GH) secretion in healthy male subjects. The study found that calcitonin suppressed spontaneous GH surges and reduced GH responses to both insulin-induced hypoglycemia and growth hormone-releasing hormone (GHRH). Additionally, calcitonin led to a transient increase in plasma prolactin
This randomized controlled trial investigated the effects of GHRH1-29NH2 and GHRP-2, both individually and in combination, on growth hormone (GH) release in children with growth hormone insufficiency and idiopathic short stature. The results indicated that while both peptides effectively stimulated GH secretion, the combination of GHRH1-29NH2 and GHRP-2 had a
